entertainment -WSS

entertainment

author：entertainment 2025-09-27 12:55:19 - browse：897

Senate Health, Education, Labor, and Pensions Committee Chairman Bernie Sanders looks at Moderna CEO Stephane Bancel as he testifies. Sitting next to Sanders, ranking member Sen. Bill Cassidy looks down – policy coverage from STAT — Committee Ranking Republican Bill Cassidy (La.) and Chairman Bernie Sanders (I-Vt.) Chip Somodevilla/Getty Images

WASHINGTON – The Senate health committee on Thursday passed a package of bills aimed at speeding generic drug competition and reining in drug middlemen business practices. But they failed to pass an ambitious reform to the pharmacy benefit manager sector, despite strong bipartisan support for it.

Chairman Bernie Sanders (I-Vt.) is pursuing the drug pricing reforms at the behest of Senate Majority Leader Chuck Schumer (D-N.Y.), who wants to hold a floor vote on an even bigger package of health bills later this year. The markup came just a day after the same panel held a major hearing on PBM and drugmakers’ role in high insulin prices.

It’s not clear when the Senate would take up that package, and while the package is bipartisan, it’s not clear whether it has enough support among House Republicans to pass in that chamber. There are a few, tamer PBM bills that the House Energy and Commerce Committee is expected to mark up May 17, but there is no indication that Senate and House lawmakers are coordinating on PBM legislation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Streamlined flu vaccines recommended by FDA advisory panel

focus

WSS

GSK’s asthma push continues as drug succeeds in Phase 3 trials

BIO to announce reorganization, senior leaders expected to depart

Harvard's David Sinclair gets blowback over aging

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

First over

GSK’s asthma push continues as drug succeeds in Phase 3 trials

leisure time

entertainment

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

Stem cell biologist probes earliest stages of human development

Novavax promises a turnaround & Lilly roils the obesity market

Why Talkspace is targeting Medicare, a tricky market

DIEP, the 'gold standard' of breast reconstruction, is under threat

The public health thinking behind the CDC’s new Covid guidance

FDA approval of Sarepta Duchenne genetic therapy gives me hope

AI for drug discovery: Experts on separating hype from reality

As demand for Covid shots wanes, Moderna seeks its next success

First over

knowledge

AltruBio raises $225 million to develop ulcerative colitis drug

Has Bernie Sanders reached the limit of his pharma bullying effort?

Longer MASH drug regimen improved liver, Akero study finds

Streamlined flu vaccines recommended by FDA advisory panel

Deliver public health messages at the right time

As billionaires fund anti

focus

focus

hotspot

focus